D

DaVita

Provides dialysis and comprehensive kidney care

Inventory Clerk

Full-Time
No salary listed
Entry
Kansas City, KS, USA
In Person
Warehouse & FulfillmentInventory Control & Cycle Counting

About the job

Requirements
  • A high school diploma or equivalent is required.
  • Additional qualifications required by individual state law must be met.
  • Strong attention to detail and follow-through skills are required.
  • Basic computer familiarity is required.
  • The candidate must be able to communicate fluently in written and verbal English, the primary language of the supplies and inventory system.
  • The candidate must have vision adequate to perform the essential duties, including repetitive use of a computer monitor.
  • The candidate must be able to lift 10 to 35 pounds unassisted and perform repetitive standing, sitting, stooping, walking, stretching, reaching, and full-range body motions.
  • The role may require unplanned Level I tasks involving potential exposure to blood, body fluids, or tissues; appropriate personal protective measures are required when exposure is possible.
  • Full COVID-19 vaccination, potentially including a booster when eligible, may be required by hospitals in the program.
Responsibilities
  • Establish and maintain inventory records for dialysis supplies, including purchase orders, inventory transaction audits, logs, files, returns, obsolete or expired items, emergency orders, and manual purchase orders; ensure appropriate supplies, medications, and equipment are available using the automated inventory system, and adjust processes for patient growth and item changes.
  • Order, receive, and issue supplies and medications daily; count supplies daily, weekly, and monthly; reissue supplies using the computerized system according to standards; and record supplies provided to other modalities, including PD, Acute, and Home Hemo.
  • Stock treatment areas daily and provide supplies, including medications, to staff.
  • Maintain inventory using first-in, first-out (FIFO) practices, prevent supplies from expiring before use, and record inventory receipts, issues, and transfers promptly.
  • Print and review scheduled system reports and inventory transaction audits daily, weekly, and monthly; submit reports to the Facility Administrator and review them with the Facility Administrator.
  • Maintain the stock room's neatness, cleanliness, and safety in accordance with policy and regulations.
  • Communicate with management, staff, purchasing agents, and vendors about supply deliveries, and notify the Facility Administrator of unusual incidents.
  • Participate in the facility quality assurance and continuous quality improvement (QA/CQI) process.
  • Perform duties of other clinic positions, including Reuse Technician and Unit Secretary/Administrative Assistant, as required.
  • Participate in team nursing and assist other staff in accordance with policies and state regulations.
  • Maintain consistent, regular attendance as scheduled.
  • Adhere to DaVita employment and teammate policies.
  • Use empathy, consideration, and respect in interactions with patients and coworkers, and seek opportunities to help teammates and patients.
  • Help foster a positive work environment.
Desired Qualifications
  • One year of related experience is preferred.
  • Familiarity with computerized inventory systems is preferred.

About the company

D

DaVita

View
Website

DaVita provides kidney care services, mainly dialysis, for patients with CKD and ESRD through a network of centers. It offers kidney health education and dietary guidance to help patients manage their condition. Care is delivered using value-based, patient-centric approaches with clinical metrics to track and improve outcomes. Its goal is to improve patient outcomes while reducing healthcare costs and building an equitable kidney-care community.

Company Size

10,001+

Company Stage

IPO

Headquarters

Denver, Colorado

Founded

1979

Get referred to DaVita

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $3.55 billion, beating estimates and growing 5%.
  • DaVita reaffirmed 2026 guidance after generating $256 million free cash flow.
  • Expanded hemodialysis deployment starts after NIPRO's FDA-approved dialyzer improved supply.

What critics are saying

  • The August 27, 2026 $15 million breach settlement covers 2.4 million people.
  • CMS's 2027 ESRD proposal still prices below DaVita's cost trends.
  • A second ransomware hit cripples payer trust and forces operational shutdowns.

What makes DaVita unique

  • DaVita's July 1, 2026 Humana deal pushes CKD intervention upstream before dialysis.
  • DaVita operated 3,266 centers across 14 countries as of June 30, 2026.
  • DaVita's CWOW platform and predictive AI monitor home dialysis patients continuously.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Paid Vacation
  • Family Planning Benefits
  • Professional Development Budget
  • Mental Health Support
  • Pet Insurance

Company News

WTWH Media
Sep 21st, 2026
MatrixCare speeds up post-acute strategy under new CEO Jonathan Lujan.

MatrixCare speeds up post-acute strategy under new CEO Jonathan Lujan. Post-acute care software company MatrixCare's newly appointed CEO, Jonathan Lujan, sees home health providers increasingly operating in a technology ecosystem rather than a closed environment - making interoperability even more crucial. Lujan wants MatrixCare to support an ecosystem resembling Apple's App Store, where the company can integrate with partners offering specialized solutions rather than trying to develop everything itself. The goal, he said, is to move data more seamlessly across care settings and technology platforms while reducing friction for providers operating on thin margins. "Home health, hospice, skilled nursing facilities, these providers face enormous workforce pressure, reimbursement complexity, regulatory burden and fragmentation across the care continuum," Lujan told Home Health Care News. "Every additional click, every aspect of workflow, every administrative task has a real cost." MatrixCare provides software solutions to over 15,000 providers in the home health, hospice, skilled nursing, senior living and life plan industries. The company announced on Sept. 1 that it had become an independent company and named Lujan its CEO. ResMed (NYSE: RMD), a medical device and digital health company, acquired MatrixCare in 2018 for $750 million. In July, Frazier Healthcare Partners agreed to buy MatrixCare, carving it out as a standalone company. The transaction means that MatrixCare will no longer have to compete internally with a large parent company for attention and investment. The change will allow the company to make faster decisions, invest with greater focus and organize itself around customer priorities, Lujan said. Lujan most recently served as CEO of Sight Growth Partners and previously served as vice president and general manager of Lifeline Vascular Care at DaVita, among other roles. Faster decisions, new initiatives. MatrixCare's new CEO has identified several priorities for the company's next chapter, including aligning product investments more closely with customer needs, improving interoperability and using AI and automation to reduce administrative work. The largest opportunity, Lujan said, is creating a tighter connection among what customers need, what MatrixCare builds and how customers ultimately realize value from its technology. AI has the potential to reduce administrative burden in clinical documentation, revenue cycle support, and other workflows, but MatrixCare is not looking to simply maximize its AI usage. "The question isn't how much AI can we put into MatrixCare," Lujan said. "Really, the question is: Where can the technology eliminate administrative work for our customers?" Lujan contrasted that approach with what he described as AI "vaporware" elsewhere in the technology market - announcements that invoke AI without delivering tools that work or solve meaningful customer problems. "We're going to make sure that what we're developing here actually solves our customers' problems," he said. While aiming to reinvigorate MatrixCare's processes and investments, Lujan has identified the post-acute workforce shortage, regulatory complexity and interoperability. The workforce shortage is the most immediate concern, he said. Post-acute providers need technology that lets a limited pool of clinicians and caregivers focus on the highest-value activities instead of spending valuable time on documentation and administrative work. At the same time, MatrixCare must help providers navigate state and federal regulations, revenue cycle management, government and commercial payers and extensive documentation requirements, Lujan said. While contending with those hurdles, the new CEO is focused on developing the tools that help post-acute care providers, including home health agencies, to help with high-stakes scenarios. "Financial tools and the revenue cycle are critically important across the entire continuum because cash is their lifeblood, and oftentimes many home health agencies are going out of business," Lujan said. Companies featured in this article: Morgan Gonzales is an award-winning reporter and associate editor of Home Health Care News. She received her bachelor's degree from the University of South Carolina and her master's from the University of Georgia. Her work has appeared in Behavioral Health Business, KFF Health News, Dallas Morning News and U.S. News and World Report. When not reporting, Morgan is usually on a trail, doing yoga, or cuddling with her cats, Ellen and Ocho.

DaVita
Aug 25th, 2026
DaVita announces new value-based partnership with Humana to expand Care for Patients with chronic kidney disease.

DaVita announces new value-based partnership with Humana to expand Care for Patients with chronic kidney disease. More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ - DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B-5. Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact. As the healthcare system aims for more impactful, value-based, preventive care, DaVita continues to lead in managing complex chronic conditions earlier. Through DaVita Integrated Kidney Care (DaVita IKC), patients receive coordinated, whole-person care that addresses the interconnected nature of cardiovascular, kidney and metabolic health - reducing fragmentation and avoidable hospital admissions. "We are in a therapeutic revolution across kidney care where upstream interventions are helping to reshape patient outcomes," said Dr. Sonia Samagh, national medical director for DaVita IKC. "Through our partnership with Humana, we are deploying advanced care that treats the whole patient, preserves kidney function and serves as a central hub for managing comorbid conditions affecting kidney health." This model builds upon the experience of DaVita's extensive network of 3,000 value-based nephrologist partners. Through continued collaboration and innovation alongside these specialists, DaVita aims to drive deeper patient engagement, impactful clinical outcomes and an unmatched care experience. The partnership will serve more than 10,000 patients. Intervening Earlier in Disease Progression The program focuses on CKD patients beginning at a pivotal point when kidney decline often accelerates but remains underdiagnosed or undertreated. By engaging patients earlier and more consistently, the model is designed to stabilize kidney function and slow disease progression. Closing Gaps in Care for Patients with Complex Conditions Not every patient can avoid kidney failure, despite the best clinical interventions. When that happens, advanced and coordinated care helps patients prepare for the next stage of their health journey through early education, advance care planning and coordinated support. Patients receive guidance on treatment options, including home dialysis and kidney transplantation, and are supported by an interdisciplinary care team that helps address barriers to care such as nutrition, transportation and mental health needs, enabling a smoother transition and better patient experience. "The kidneys are often an early indicator that something else is happening systemically within the body. To truly care for the kidneys, we must uncover and address those underlying health issues," said Dr. Samagh. "When we do this, we can work to preserve kidney function, support reduced hospitalizations and enhance patients' quality of life." About DaVita Inc. DaVita (NYSE: DVA) is a healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita cares for patients at every stage and setting along their kidney health journey - from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in dialysis centers, in the hospital and in skilled nursing facilities. As of June 30, 2026, DaVita served approximately 298,500 patients at 3,266 outpatient dialysis centers, of which 2,671 centers were located in the United States and 595 centers were located in 14 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About. Media Contacts SOURCE DaVita

Yahoo Finance
Aug 5th, 2026
DaVita HealthCare Q2 earnings beat estimates at $4.02 per share on $3.55B revenue

DaVita HealthCare reported second-quarter earnings of $4.02 per share, slightly exceeding the consensus estimate of $4.01. This represents a 0.25% earnings surprise for the kidney dialysis provider. Quarterly revenues reached $3.55 billion, surpassing estimates by 0.61%. Year-over-year comparisons show earnings increased from $2.95 per share and revenues from $3.38 billion in the same period last year. The company has exceeded consensus earnings estimates three times over the past four quarters and topped revenue estimates all four quarters. DaVita shares have surged 105.7% year-to-date, significantly outpacing the S&P 500's 11% gain. The company currently holds a Zacks Rank of Hold, suggesting shares are expected to perform in line with the broader market near-term.

MarketBeat
Aug 5th, 2026
DaVita Q2 earnings call highlights.

DaVita Q2 earnings call highlights. August 5, 2026 Key points. * DaVita reaffirmed its 2026 outlook after reporting second-quarter adjusted operating income of $579 million, adjusted EPS of $4.02 and free cash flow of $256 million. Treatment growth exceeded expectations, helped by lower patient mortality, and full-year nominal volume growth is expected near the top of the company's 25-50 basis-point range. * Revenue per treatment fell sequentially by about $2 due to timing effects, lower phosphate-binder revenue and reduced commercial insurance mix. DaVita still expects full-year revenue-per-treatment growth of 1%-2%, while patient-care costs per treatment declined by about $3. * DaVita plans to broadly deploy expanded hemodialysis using existing machines after securing dialyzer supplies, with management citing clinical results showing non-inferiority to HDF. The company also repurchased shares, completed a $200 million investment in Elara Caring and maintained its guidance midpoint of $2.2 billion in adjusted operating income and $14.65 in adjusted EPS. * MarketBeat previews top five stocks to own in September. DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules. Second-quarter adjusted operating income was $579 million, adjusted earnings per share were $4.02, and free cash flow totaled $256 million, Chief Financial Officer Joel Ackerman said on the company's earnings call. U.S. dialysis treatments increased 56 basis points from the second quarter of 2025, with treatments per normalized day rising by the same amount. Ackerman said volume growth came in slightly above expectations, primarily because mortality was lower than anticipated. That benefit was partly offset by fewer patient admissions from closed Fresenius clinics and a higher-than-expected level of missed treatments. DaVita now expects full-year nominal treatment growth near the upper end of its prior range of 25 to 50 basis points. On a calendar-normalized basis, that would translate to growth of roughly 50 to 75 basis points, according to Ackerman. Revenue per treatment declines sequentially. Revenue per treatment declined by about $2 from the first quarter. Ackerman attributed the sequential decrease to favorable revenue timing in the first quarter, lower revenue from phosphate binders and a decline in commercial insurance mix related to expired Affordable Care Act subsidies. Although revenue per treatment was up 3.6% in the first half compared with the first half of 2025, the company continues to expect full-year growth of 1% to 2%. The midpoint of that outlook implies slightly negative revenue-per-treatment growth in the second half versus the same period a year earlier, driven by lower commercial mix, lower phosphate-binder revenue and a favorable fourth-quarter 2025 comparison related to aged-claim resolutions. Discover more Company News Options Profit Calculator Market Cap Calculator Patient care costs per treatment fell about $3 sequentially, reflecting labor and fixed-cost leverage from higher treatment volume and lower phosphate-binder costs. Higher benefit costs partly offset those improvements. DaVita expects total cost per treatment to grow between 1.25% and 2.25% for the full year. During the question-and-answer session, Ackerman said U.S. dialysis general and administrative expenses increased 10% in the quarter, while enterprise adjusted operating income increased about 5%. Phosphate binders and Medicare policy. Chief Executive Officer Javier Rodriguez highlighted the transition of phosphate binders into the Medicare dialysis bundle. He said the policy change, which began more than two years ago after advance notice from the Centers for Medicare & Medicaid Services, has expanded access to clinically preferred therapies. Rodriguez said the number of patients relying on over-the-counter options such as TUMS has declined by more than 50%, allowing more patients to use treatments intended to better manage phosphate levels and reduce risks associated with cardiovascular complications and bone fractures. CMS in late June issued its proposed rule for the 2027 ESRD prospective payment system. Rodriguez said the proposal includes a Medicare base-rate update and the addition of phosphate binders to the bundled dialysis payment beginning next year. He said the proposed payment update remains below the industry's cost trends because of methodology changes and TDAPA-related dynamics. DaVita is providing feedback during the rulemaking process and hopes the final rule better reflects the cost of providing care. Rodriguez added that CMS has reduced its projected phosphate-binder spending estimate by nearly $500 million since the medications' initial transition. DaVita supports ending the TDAPA period after two years, though the company said its ultimate 2027 financial effect will depend on the final dialysis-bundle update. Expanded HD deployment planned. DaVita plans to begin broadly deploying expanded hemodialysis, or expanded HD, across its network in coming quarters after securing supplies of compatible dialyzers. The technology is intended to clear a broader group of toxins known as middle molecules. Rodriguez cited results from the MOTheR clinical trial, which compared expanded HD using medium cut-off dialyzers with hemodiafiltration, or HDF. He said expanded HD was shown to be non-inferior to HDF on a composite endpoint including all-cause mortality and major cardiovascular events. Unlike HDF, expanded HD can be delivered using DaVita's existing dialysis machines, which Rodriguez said should allow for faster implementation without significant capital investment. He said a recent Food and Drug Administration approval of a new expanded-HD dialyzer from NIPRO improved supply availability and economics. Management said the near-term financial impact of deployment is included in 2026 guidance and is not expected to be significant. Ackerman said a positive economic impact would depend on a mortality benefit and is not expected to begin until 2028. Capital allocation and outlook. DaVita closed its $200 million minority investment in Elara Caring in July. Ackerman said the home-health provider is expected to generate a small other-income benefit in 2026, likely in the mid-single-digit millions. The company repurchased 2.2 million shares in the second quarter and another 183,000 shares after quarter-end. Its leverage ratio was 3.37 times consolidated EBITDA, within its stated 3.0 to 3.5 times target range. DaVita also issued $500 million of incremental debt during the quarter, primarily to repay revolver borrowings. International adjusted operating income was $25 million, in line with expectations. Integrated Kidney Care, or IKC, generated $40 million of adjusted operating income, above expectations because revenue was recognized earlier than anticipated. Management still expects International and IKC each to contribute about $20 million to full-year enterprise adjusted operating income growth. DaVita reaffirmed full-year guidance with a midpoint of $2.2 billion for adjusted operating income and $14.65 for adjusted earnings per share. Ackerman said the company expects adjusted operating income in the fourth quarter to be $50 million to $100 million higher than in the third quarter, with IKC revenue timing the largest driver. About DaVita (NYSE:DVA). DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being. Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider DaVita, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list. While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

The Durango Herald
Aug 4th, 2026
DaVita HealthCare: Q2 earnings snapshot.

DaVita HealthCare: Q2 earnings snapshot. Tuesday, Aug 4, 2026 2:16 PM MT DENVER (AP) - DENVER (AP) - DaVita HealthCare Partners Inc. (DVA) on Tuesday reported net income of $265.4 million in its second quarter. On a per-share basis, the Denver-based company said it had profit of $4.02. The kidney dialysis provider posted revenue of $3.55 billion in the period. DaVita HealthCare expects full-year earnings in the range of $14.10 to $15.20 per share. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on DVA at https://www.zacks.com/ap/DVA Sponsored content.